Intravenous topiramate: Safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate

Epilepsia

Volumn 54, Issue 6, 2013, Pages 1106-1111

  Clark, Anne M ^a   Kriel, Robert L ^b   Leppik, Ilo E ^b,c,d   White, James R ^e   Henry, Thomas R ^d   Brundage, Richard C ^b   Cloyd, James C ^b,d  

^a Upsher Smith Laboratories Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MINCEP Epilepsy Care   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MINNESOTA EPILEPSY GROUP   (United States)

Author keywords

Antiepileptic drug; Intravenous; Pharmacokinetics; Topiramate

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; CARBAMAZEPINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE;

ADULT; AGED; ARM WEAKNESS; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; EPILEPSY; FEMALE; HEART RATE; HUMAN; INJECTION SITE REACTION; LIMB WEAKNESS; MAINTENANCE THERAPY; MALE; MIGRAINE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICONVULSANTS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; EPILEPSY; FEMALE; FRUCTOSE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS;

EID: 84878561941     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12165     Document Type: Article

References (30)

1. Baillie TA,. (1981) The use of stable isotopes in pharmacological research. Pharmacol Rev 33: 81-132.
2. Bittigau P, Sifringer M, Ikonomidou C,. (2003) Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 993: 103-114; discussion 123-104.
3. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J,. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67: 400-406.
4. Cha BH, Silveira DC, Liu X, Hu Y, Holmes GL,. (2002) Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res 51: 217-232.
5. Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC, Cloyd JC,. (2013) Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia In press.
6. Doose DR, Streeter AJ,. (2002) Topiramate-chemistry, biotransformation and pharmacokinetics. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA, pp 727-734.
7. Doose DR, Walker SA, Gisclon LG, Nayak RK,. (1996) Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 36: 884-891.
8. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK,. (1988) Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 29: 662.
9. Filippi L, la Marca G, Fiorini P, Poggi C, Cavallaro G, Malvagia S, Pellegrini-Giampietro DE, Guerrini R,. (2009) Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 50: 2355-2361.
10. Filippi L, Poggi C, la Marca G, Furlanetto S, Fiorini P, Cavallaro G, Plantulli A, Donzelli G, Guerrini R,. (2010) Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr 157: 361-366.
11. Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, Volpe JJ, Jensen FE,. (2004) Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 24: 4412-4420.
12. Garnett WR,. (2000) Clinical pharmacology of topiramate: a review. Epilepsia 41 (Suppl. 1): S61-S65.
13. Gisclon LG, Curtin CR, Kramer LD,. (1994) The steady-state pharmacokinetics of phenytoin and topiramate in epileptic patients on monotherapy, and during combination therapy. Epilepsia 35: 54.
14. Glass HC, Poulin C, Shevell MI,. (2011) Topiramate for the treatment of neonatal seizures. Pediatr Neurol 44: 439-442.
15. Glier C, Dzietko M, Bittigau P, Jarosz B, Korobowicz E, Ikonomidou C,. (2004) Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol 187: 403-409.
16. Holden KR, Mellits ED, Freeman JM,. (1982) Neonatal seizures. I. Correlation of prenatal and perinatal events with outcomes. Pediatrics 70: 165-176.
17. Janssen Pharmaceuticals, Inc. (2012) Topamax package insert, Titusville, NJ.
18. Johannessen SI,. (1997) Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 38 (Suppl. 1): S18-S23.
19. Koh S, Tibayan FD, Simpson JN, Jensen FE,. (2004) NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 45: 569-575.
20. Lee SR, Kim SP, Kim JE,. (2000) Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett 281: 183-186.
21. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R,. (2003) Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60: 1483-1488.
22. Niebauer M, Gruenthal M,. (1999) Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 837: 263-269.
23. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, Paneth N, Minnigh B, Alvin J,. (1999) Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 341: 485-489.
24. Ronen GM, Penney S, Andrews W,. (1999) The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr 134: 71-75.
25. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR,. (1996) Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37: 774-780.
26. Sheth RD, Hobbs GR, Mullett M,. (1999) Neonatal seizures: incidence, onset, and etiology by gestational age. J Perinatol 19: 40-43.
27. Silverstein FS, Ferriero DM,. (2008) Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 39: 77-79.
28. Tekgul H, Gauvreau K, Soul J, Murphy L, Robertson R, Stewart J, Volpe J, Bourgeois B, du Plessis AJ,. (2006) The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics 117: 1270-1280.
29. Wu WN, Heebner JB, Streeter AJ,. (1994) Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharm Res 11: S336.
30. Yang Y, Shuaib A, Li Q, Siddiqui MM,. (1998) Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 804: 169-176.